- Home
- » Tags
- » Fosaprepitant
Top View
- (12) United States Patent (10) Patent No.: US 9.446,029 B2 Boscan Et Al
- Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
- Estonian Statistics on Medicines 2013 1/44
- Effects of Rolapitant on Nausea/Vomiting in Patients With
- Drug Review: Fosaprepitant
- Neurokinin-1 (NK1) Receptor Antagonists and Combinations
- Spotlight on the Perioperative Use of Maropitant Citrate Bonnie L
- Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonist +
- List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
- EMEND (Aprepitant and Fosaprepitant) RATIONALE FOR
- 2013 National Hospital Ambulatory Medical Care Survey Emergency
- Responding to the Challenge of Chemotherapy-Induced Nausea and Vomiting
- Pilot Study Evaluating MK-869 for Prevention of Nausea and Vomiting
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
- Akynzeo Injection (Fosnetupitant Palonosetron), Cinvanti, Emend (Aprepitant), Emend Injection (Fosaprepitant), Varubi (Rolapitant)
- Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0231688 A1
- IVEMEND, INN-Fosaprepitant Dimeglumine
- Neurokinin-1 Receptor Antagonists in Preventing Postoperative Nausea and Vomiting a Systematic Review and Meta-Analysis
- 6|18 Fosaprepitant and Aprepitant For
- Specialty Payment Model Opportunities and Assessment
- Overview of the Neurokinin-1 Receptor Antagonists
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- SCNAUSEA – Guidelines for Preventing and Treatment of Chemotherapy-Induced Nausea
- Guidelines for ATC Classification and DDD Assignment 2021
- The Neurokinin-1 Receptor Antagonist Aprepitant: an Intelligent Bullet Against Cancer?
- PONV Prophylaxis Guidelines
- Drug Policy: Emend™ (Aprepitant Oral Or Fosaprepitant), Cinvanti™ (Aprepitant Injection), and Varubi™ (Rolapitant Oral)
- EMEND (Fosaprepitant) for Injection, for Intravenous Use Initial U.S
- WO 2017/060488 Al 13 April 2017 (13.04.2017) P O PCT
- Guidelines for ATC Classification and DDD Assignment 2013
- Preliminary Results of a Cochrane Systematic Review
- Prospective Observational Study of the Use of Omeprazole and Maropitant
- Entscheidung Der Arzneimittelbehörde
- EMEND (Fosaprepitant Dimeglumine)
- Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis
- Substance P) Receptor
- Antiemetics for Oncology – Commercial Medical Benefit Drug
- Fosaprepitant for Injection PI
- 5-HT3 Receptor Antagonists and Combinations)
- Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
- Antiemetic Therapy
- ADAP Quarterly NDC Special Review
- Class Update with New Drug Evaluation: Antiemetics
- NEPA, a New Fixed Combination of Netupitant and Palonosetron, Is A